Detalhe da pesquisa
1.
[FDG PET/CT FOR TREATMENT RESPONSE ASSESSMENT IN CANCER].
Harefuah
; 160(7): 462-467, 2021 Jul.
Artigo
em Hebraico
| MEDLINE | ID: mdl-34263575
2.
Uterine cancer in Jewish Israeli BRCA1/2 mutation carriers.
Cancer
; 125(5): 698-703, 2019 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30489631
3.
Dexrazoxane added to doxorubicin-based adjuvant chemotherapy of breast cancer: a retrospective cohort study with a comparative analysis of toxicity and survival.
Anticancer Drugs
; 28(7): 787-794, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28562379
4.
Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.
Gynecol Oncol
; 140(2): 199-203, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26723501
5.
Liposome-encapsulated doxorubicin citrate (Myocet) for treatment of recurrent epithelial ovarian cancer: a retrospective analysis.
Anticancer Drugs
; 25(1): 101-5, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24263191
6.
[Intravenous vinorelbine as first line chemotherapy in patients with castration-resistant prostate cancer].
Harefuah
; 153(12): 731-4, 752, 2014 Dec.
Artigo
em Hebraico
| MEDLINE | ID: mdl-25654915
7.
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study.
Clin Cancer Res
; 30(1): 50-62, 2024 01 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37939124
8.
Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience.
Int J Gynecol Cancer
; 23(3): 475-80, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23435437
9.
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial.
J Clin Oncol
; 41(30): 4768-4778, 2023 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37643382
10.
Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences?
Oncologist
; 17(12): 1534-40, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22622146
11.
Palliative sedation at home.
J Palliat Care
; 25(1): 5-11, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19445337
12.
Recurrence of endometrial carcinoma presenting as vulvar lesions.
Int J Gynaecol Obstet
; 145(1): 123-124, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30653661
13.
Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy.
NPJ Breast Cancer
; 5: 41, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31728408
14.
An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin.
Cancer Chemother Pharmacol
; 61(4): 695-702, 2008 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-17549475
15.
Primary amelanotic melanoma of the vagina.
Onkologie
; 31(8-9): 474-6, 2008 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-18787356
16.
Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry.
NPJ Breast Cancer
; 3: 32, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28900632
17.
Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry.
NPJ Breast Cancer
; 3: 33, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28900633
18.
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
J Clin Oncol
; 33(3): 244-50, 2015 Jan 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-25366685
19.
Pegylated liposomal doxorubicin/carboplatin combination in ovarian cancer, progressing on single-agent pegylated liposomal doxorubicin.
World J Clin Oncol
; 3(10): 137-41, 2012 Oct 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-23198277
20.
A 67-year-old woman with BRCA 1 mutation associated with pancreatic adenocarcinoma.
J Gastrointest Cancer
; 42(3): 160-4, 2011 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-20711688